AN2 Therapeutics, Inc., (ANTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANTX Stock Price Chart Interactive Chart >
ANTX Price/Volume Stats
| Current price | $9.63 | 52-week high | $23.58 |
| Prev. close | $9.82 | 52-week low | $6.88 |
| Day low | $9.58 | Volume | 12,200 |
| Day high | $10.05 | Avg. volume | 26,092 |
| 50-day MA | $11.36 | Dividend yield | N/A |
| 200-day MA | $11.85 | Market Cap | 186.85M |
AN2 Therapeutics, Inc., (ANTX) Company Bio
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Latest ANTX News From Around the Web
Below are the latest news stories about AN2 THERAPEUTICS INC that investors may wish to consider to help them evaluate ANTX as an investment opportunity.
AN2 Therapeutics GAAP EPS of -$0.61
|
AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent HighlightsMENLO PARK, Calif., March 29, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022. |
AN2 Therapeutics to Participate in Upcoming Investor ConferencesMENLO PARK, Calif., February 28, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in March. |
AN2 Therapeutics to Present at SVB Securities Global Biopharma ConferenceMENLO PARK, Calif., January 31, 2023--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference. |
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
ANTX Price Returns
| 1-mo | -15.53% |
| 3-mo | 1.05% |
| 6-mo | -44.59% |
| 1-year | -36.10% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.05% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...